Study Groups
WWARN facilitates a number of collaborative Study Groups to undertake individual patient data meta-analyses to answer specific research questions about malaria treatments and antimalarial drug resistance. Gathering and combining data sets from multiple studies increases sample sizes, so that effects, including smaller effects, and effects on sub-populations can be identified with greater certainty. Working together and combining data from different regions and populations is improving our understanding of drug resistance and strengthening global efforts to control and eventually eliminate malaria.
Analysis of how age impacts the effect of primaquine dose on gastrointestinal tolerability in patients with Plasmodium vivax and Plasmodium ovale mala...
show more
A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended ...
show more
Analysis of how age impacts the effect of primaquine dose on efficacy in patients with Plasmodium vivax and Plasmodium ovale malaria
Sub-study groups include the Artemether-Lumefantrine / ARV PK Study Group and the ACT-ARV Safety Study Group.
The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of mala...
show more
Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the prop...
show more
A pooled analysis of methaemoglobin as a marker of primaquine antihypnozoite activity in Plasmodium vivax malaria
The Plasmodium vivax fever study group aims to estimate parasitaemia thresholds for febrile patients who present for treatment and determine the ...
show more
This Study Group aims to bring together and explore the latest evidence on the prevalence of molecular markers associated with antimalarial drug resis...
show more
This Study Group will explore the link between P. vivax recurrence and prior P. falciparum treatment, including increased risk of vivax para...
show more
Characterising the population pharmacokinetic properties of ivermectin in children and adults to inform optimal dosing of ivermectin
This is an extension of the WWARN Haemoglobin-Haematocrit Relationship in Malaria Study Group and the Antimalarial–Antiretroviral Analy...
show more
Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the...
show more
The paediatric single low-dose (SLD) primaquine efficacy study group aims to assess and compare the efficacy of SLD primaquine for transmission blocki...
show more
The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of mala...
show more
Exploring the impact of malaria during pregnancy on infant anaemia, malaria, morbidity and growth – an individual participant meta-analysis.
Analysis of the effect of primaquine dose on the efficacy, safety and tolerability in patients with Plasmodium vivax malaria
Baseline information on parasitological response to ACTs in AsiaA pooled analysis to assess the baseline early parasitological response after artemisi...
show more
Parasite clearance after treatment with an artemisinin monotherapy or ACTThis Study Group characterises parasite clearance stratified by location, tre...
show more
Effect of AS-AQ mg/kg dosing strategies on the risk of treatment failureA pooled analysis to assess the impact of weight adjusted (mg/kg) dose variati...
show more
A pooled analysis that assessed the effect of various nutritional indicators in treatment outcome in children aged 6-59 months treated with artemisini...
show more
A population pharmacokinetic/pharmacodynamic model of pyrimethamine and sulfadoxine in participants who received either sulfadoxine-pyrimethamine (SP)...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform dosageA pooled piperaquine pharmacokinetic analysed the exposure to piperaquine i...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform antimalarial dosageA pooled pharmacokinetic/pharmacodynamics (PK/PD) analysis of ...
show more
Baseline information on parasitological response to ACTs in AfricaA pooled analysis to assess the baseline early parasitological response after artemi...
show more
Role of candidate molecular markers of lumefantrine and amodiaquine resistanceThe Artesunate-Amodiaquine/Artemether Lumefantrine (AS-AQ/AL) Molecular ...
show more
Analysing PK/PD data to identify inadequate drug exposure and inform dosageA pooled lumefantrine pharmacokinetic-pharmacodynamic (PK/PD) analysis is b...
show more
Analysis of risk factors of Plasmodium vivax early and late recurrence. Published in July 2018.
The AL Dose Impact Study Group was first established in 2011. The Study Group first met in December 2011 at the ASTMH Annual Meeting to discuss the St...
show more
A pooled analysis on the relationship between K13 molecular marker and parasite clearance data. The Study Group closed to new participants in Dec...
show more
Effect of DP mg/kg dosing strategies on the risk of treatment failureA pooled analysis to assess the impact of weight adjusted (mg/kg) dose variations...
show more
Analysis of the consequences of symptomatic Plasmodium vivax infections on anaemia before and after antimalarial treatment
A pooled analysis of Plasmodium falciparum gametocyte carriageThe purpose of this Study Group is to assess the risk factors for treatment failure asso...
show more
Determining the optimal Artemether-lumefantrine antimalarial dosing for young children and pregnant women: A pharmacokinetic-pharmacodynamic meta...
show more